Literature DB >> 18173966

GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Bo Ahrén1.   

Abstract

Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18173966     DOI： 10.1007/s11892-007-0056-9

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  50 in total

1.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Authors:  N Matikainen; S Mänttäri; A Schweizer; A Ulvestad; D Mills; B E Dunning; J E Foley; M-R Taskinen
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

2.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Authors:  M A Nauck; U Niedereichholz; R Ettler; J J Holst; C Orskov; R Ritzel; W H Schmiegel
Journal:  Am J Physiol       Date:  1997-11

Review 3.  Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors:  R Mentlein
Journal:  Regul Pept       Date:  1999-11-30

Review 4.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

5.  Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

Authors:  M A Nauck; M Hompesch; R Filipczak; T D T Le; M Zdravkovic; J Gumprecht
Journal:  Exp Clin Endocrinol Diabetes       Date:  2006-09       Impact factor: 2.949

6.  Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

Authors:  A J Garber; A Schweizer; M A Baron; E Rochotte; S Dejager
Journal:  Diabetes Obes Metab       Date:  2007-03       Impact factor: 6.577

7.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors:  Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

8.  Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

Authors:  Adrian Vella; Gerlies Bock; Paula D Giesler; Duane B Burton; Denise B Serra; Monica Ligueros Saylan; Beth E Dunning; James E Foley; Robert A Rizza; Michael Camilleri
Journal:  Diabetes       Date:  2007-02-15       Impact factor: 9.461

Review 9.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

Authors:  J J Holst; C F Deacon
Journal:  Diabetes       Date:  1998-11       Impact factor: 9.461

10.  Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.

Authors:  Mark S Fineman; Larry Z Shen; Kristin Taylor; Dennis D Kim; Alain D Baron
Journal:  Diabetes Metab Res Rev       Date:  2004 Sep-Oct       Impact factor: 4.876
View more
  14 in total

Review 1.  Central control of body weight and appetite.

Authors:  Stephen C Woods; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

Review 2.  Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.

Authors:  G R Kolar; S M Grote; G L C Yosten
Journal:  J Intern Med       Date:  2016-06-16       Impact factor: 8.989

Review 3.  Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors.

Authors:  Qin Fu; Qian Shi; Toni M West; Yang K Xiang
Journal:  J Cardiovasc Pharmacol       Date:  2017-08       Impact factor: 3.105

4.  Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis.

Authors:  M A Abdul-Ghani; K Williams; M Kanat; Y Altuntas; R A DeFronzo
Journal:  J Endocrinol Invest       Date:  2012-04-18       Impact factor: 4.256

5.  GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.

Authors:  Lena Ohlsson; Alison B Kohan; Patrick Tso; Bo Ahrén
Journal:  Regul Pept       Date:  2014-02-28

6.  A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.

Authors:  P Marchetti; R Lupi; M Bugliani; C L Kirkpatrick; G Sebastiani; F A Grieco; S Del Guerra; V D'Aleo; S Piro; L Marselli; U Boggi; F Filipponi; L Tinti; L Salvini; C B Wollheim; F Purrello; F Dotta
Journal:  Diabetologia       Date:  2012-09-11       Impact factor: 10.122

7.  Gastrointestinal complications of diabetes mellitus.

Authors:  Babu Krishnan; Shithu Babu; Jessica Walker; Adrian B Walker; Joseph M Pappachan
Journal:  World J Diabetes       Date:  2013-06-15

Review 8.  Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.

Authors:  Bo Ahrén
Journal:  Nat Rev Drug Discov       Date:  2009-04-14       Impact factor: 84.694

9.  Experimental diabetes treated with trigonelline: effect on key enzymes related to diabetes and hypertension, β-cell and liver function.

Authors:  Khaled Hamden; Amel Bengara; Zahra Amri; Abdelfattah Elfeki
Journal:  Mol Cell Biochem       Date:  2013-06-11       Impact factor: 3.396

10.  Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience.

Authors:  Roberto Anichini; Sabrina Cosimi; Alberto Di Carlo; Paola Orsini; Alessandra De Bellis; Giuseppe Seghieri; Flavia Franconi; Fabio Baccetti
Journal:  Diabetes Metab Syndr Obes       Date:  2013-04-08       Impact factor: 3.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.